<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438034</url>
  </required_header>
  <id_info>
    <org_study_id>2011P002885</org_study_id>
    <nct_id>NCT01438034</nct_id>
  </id_info>
  <brief_title>Kisspeptin in the Evaluation of Delayed Puberty</brief_title>
  <official_title>Kisspeptin in the Evaluation of Delayed Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some children with delayed puberty will eventually enter puberty on their own. However, some
      children with delayed puberty have a permanent condition and require medical treatment to
      undergo puberty. Right now, there is no reliable diagnostic tool to tell whether a child's
      delayed puberty will be self-resolving or permanent. The hormone kisspeptin has the potential
      to prospectively diagnose adolescents with self-resolving or permanent delayed puberty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are seeking boys (ages 13.5-17 years) and girls (ages 12-17) years with a
      diagnosis of delayed puberty. Study participation involves 2 outpatient visits and two
      hospital admissions (one 11-hour, overnight admission and one 6-hour day admission) when
      subjects will receive two investigational drugs, the naturally occurring hormones kisspeptin
      and gonadotropin-releasing hormone (GnRH). Subjects will then be followed every 6 months
      until they reach 18 years of age to determine if their pubertal delay was self-resolved or
      permanent. Individuals interested in learning more may call 617-726-8484.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change in luteinizing hormone (LH) in response to kisspeptin</measure>
    <time_frame>Within 30 minutes of administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Delayed Puberty</condition>
  <condition>Kallmann Syndrome</condition>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <condition>GnRH Deficiency</condition>
  <arm_group>
    <arm_group_label>kisspeptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kisspeptin 112-121</intervention_name>
    <description>0.24 nmol/kg</description>
    <arm_group_label>kisspeptin</arm_group_label>
    <other_name>metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>75 ng/kg</description>
    <arm_group_label>kisspeptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adolescent Boys

          -  ages 13.5-17 years

          -  testicular volume &lt;4 mL OR 4-8 ml with no change in the past 6 months by Prader
             orchidometer

          -  first morning (before 9AM) LH &lt;2 mIU/mL and testosterone &lt;50 ng/dL

        Adolescent Girls

          -  ages 12-17 years

          -  Tanner stage I OR II breast development with no change in the past 6 months

          -  first morning (before 9AM) LH &lt;2 mIU/mL and estradiol &lt;20 pg/ml

        All Subjects:

          -  bone age less than chronological age

          -  weight â‰¥ 28 kg

          -  body mass index &gt;10th percentile and &lt;+3 SDS for bone age

          -  blood pressure &gt;5th percentile and &lt;95th percentile for bone age and height

          -  white blood cell counts, platelet counts, electrolytes, thyroid stimulating hormone
             (TSH), free thyroxine (T4) within reference range for age

          -  erythrocyte sedimentation rate &lt;2X the upper limit of the reference range for age

          -  hemoglobin within reference range for girls of the same chronological age

          -  blood urea nitrogen (BUN), creatinine, prolactin not elevated

          -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no more than 2X
             the upper limit of the reference range

          -  Insulin-like growth factor 1 (IGF-1) within reference range for bone age

        Exclusion Criteria:

        All Subjects:

          -  history or presence of underlying condition that could cause delayed puberty (chronic
             illness, weight loss, abnormal cranial magnetic resonance imaging (MRI))

          -  history of an allergic drug reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie B Seminara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>617-726-8484</phone>
    <email>MGHKisspeptinResearch@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yee-Ming Chan, MD, PhD</last_name>
      <phone>617-726-9260</phone>
      <email>YMCHAN@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie B Seminara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yee-Ming Chan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kallmann Syndrome</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Puberty, Delayed</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

